Altimmune Q1 Call Reveals $150M Cash Cushion and Pipeline Advancements
Altimmune reported a cash and marketable securities balance of $150 million at end of Q1 2026, extending its operational runway into late 2027. Management outlined strategic priorities to advance its NASH and vaccine programs, with a Phase 2 trial planned for its COVID-19 vaccine candidate in H2 2026.
1. Q1 Cash Position
Altimmune ended Q1 2026 with $150 million in cash and marketable securities, providing funding into late 2027 without additional financing. Management emphasized this strong liquidity as a foundation for advancing its clinical programs.
2. Pipeline and Strategic Priorities
The company plans to initiate a Phase 2 trial for its COVID-19 vaccine candidate in H2 2026, while also progressing its NASH treatment through dose-ranging studies. Business development efforts remain focused on licensing and collaboration opportunities to maximize program value.